Allergan's Ubrogepant Succeeds In Second Acute Migraine Phase III Study

19:24 EDT 27 Apr 2018 | SCRIP

The company intends to seek US FDA approval in the first half of 2019 for its CGRP inhibitor and believes...

More From BioPortfolio on "Allergan's Ubrogepant Succeeds In Second Acute Migraine Phase III Study"